Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Leukemia, Myeloid, Acute 11Leukemia, Myelomonocytic, Acute 10Leukemia, Monocytic, Acute 10Leukemia, Megakaryoblastic, Acute 10Leukemia, Erythroblastic, Acute 10Congenital Abnormalities 8Breast Neoplasms 8Anemia, Refractory, with Excess of Blasts 5Lymphoma, Non-Hodgkin 4Leukemia, Myelomonocytic, Chronic 4Leukemia, Eosinophilic, Acute 4Leukemia, Basophilic, Acute 4Leukemia 4Gliosarcoma 4Glioblastoma 4Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Pancreatic Neoplasms 3Melanoma 3Medulloblastoma 3Leukemia, Lymphocytic, Chronic, B-Cell 3Inflammatory Breast Neoplasms 3Breast Neoplasms, Male 3Blast Crisis 3Wilms Tumor 2Urinary Bladder Neoplasms 2Thyroid Neoplasms 2Thrombocythemia, Essential 2Sarcoma, Ewing 2Sarcoma 2Rhabdomyosarcoma 2

Interventions

veliparib 1tipifarnib 1pazopanib 1Mitozytrex 1Mitomycin 1Immunoglobulin G 1Erlotinib Hydrochloride 1Disulfides 1Bevacizumab 1ARQ 197 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Solid Neoplasm × tipifarnib × Clear all
NCT00085553 2018-05-18

Tipifarnib and Erlotinib Hydrochloride in Treating Patients With Advanced Solid Tumors

National Cancer Institute (NCI)

Phase 1 Completed
29 enrolled

Solid Neoplasm

Data powered by HemOnc (CC BY 4.0) Colophon âš¡